We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+32.17%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$5.01B
AUM Growth
+$300M
Cap. Flow
-$394M
Cap. Flow %
-7.86%
Top 10 Hldgs %
36.48%
Holding
142
New
15
Increased
17
Reduced
27
Closed
32

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$105M
2
BIIB icon
Biogen
BIIB
+$66.5M
3
ELV icon
Elevance Health
ELV
+$65.4M
4
SRRK icon
Scholar Rock
SRRK
+$27.5M
5
ARGX icon
argenx
ARGX
+$24.2M

Top Sells

Rank Stock Value
1
HUM icon
Humana
HUM
+$115M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$85.3M
3
BAX icon
Baxter International
BAX
+$84.5M
4
CI icon
Cigna
CI
+$66.2M
5
ABBV icon
AbbVie
ABBV
+$49.2M

Sector Composition

Rank Sector Weight
1 Healthcare 97.96%
2 Industrials 1.01%
3 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PHGE icon
101
BiomX
PHGE
$1.94M
$1.26M 0.03%
23,777
-189
-0.8% -$11.9K
CMMB
102
Chemomab Therapeutics
CMMB
$11.4M
$1.14M 0.02%
560,319
– –
GERN icon
103
Geron
GERN
$911M
$1.02M 0.02%
+485,000
New +$943K
VIR icon
104
Vir Biotechnology
VIR
$1.46B
$1.02M 0.02%
+101,000
New +$923K
AGIO icon
105
Agios Pharmaceuticals
AGIO
$2.08B
$1M 0.02%
+45,000
New +$1.01M
CALC icon
106
CalciMedica
CALC
$11.7M
$851K 0.02%
297,380
– –
ELEV
107
DELISTED
Elevation Oncology
ELEV
$806K 0.02%
1,500,000
– –
AFIB
108
DELISTED
Acutus Medical Inc
AFIB
$535K 0.01%
2,648,386
– –
OMIC
109
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
$249K 0.01%
18,023
– –
ABBV icon
110
AbbVie
ABBV
$466B
– –
-330,000
Closed -$49.2M
AKRO
111
DELISTED
Akero Therapeutics
AKRO
– –
-350,000
Closed -$17.7M
ALT icon
112
Altimmune
ALT
$568M
– –
-100,000
Closed -$260K
APLS
113
CALL
DELISTED
Apellis Pharmaceuticals
APLS
– –
-77,500
Closed -$2.95M
ARQT icon
114
Arcutis Biotherapeutics
ARQT
$3.49B
– –
-1,914,479
Closed -$10.2M
AZN icon
115
CALL
AstraZeneca
AZN
$269B
– –
-125,000
Closed -$16.9M
BAX icon
116
Baxter International
BAX
$12.8B
– –
-2,239,900
Closed -$84.5M
BCAB icon
117
BioAtla
BCAB
$5.34M
– –
-20,186
Closed -$1.72M
CI icon
118
Cigna
CI
$78.5B
– –
-231,500
Closed -$66.2M
DXCM icon
119
CALL
DexCom
DXCM
$29B
– –
-50,000
Closed -$4.67M
EPIX
120
DELISTED
ESSA Pharma
EPIX
– –
-842,366
Closed -$2.6M
GDRX icon
121
GoodRx Holdings
GDRX
$1.09B
– –
-1,595,000
Closed -$8.98M
DMRA
122
Damora Therapeutics, Inc. Ordinary Shares
DMRA
$1.75B
– –
-36,992
Closed -$665K
IMTX icon
123
CALL
Immatics
IMTX
$1.23B
– –
-125,000
Closed -$1.45M
KVUE icon
124
CALL
Kenvue
KVUE
$38B
– –
-250,000
Closed -$5.02M
KVUE icon
125
Kenvue
KVUE
$38B
– –
-312,404
Closed -$6.27M
2 3 4
5
6

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q4 2023 Portfolio in Review

As of Q4 2023, OrbiMed held 142 positions worth $5.01B, up 6.4% from $4.71B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

OrbiMed withdrew a net $394M in Q4 2023, closing 32 positions and reducing 27 holdings. Its most notable exit was Mirati Therapeutics, Inc. Common Stock, an estimated $85.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Industrials and Consumer Staples.

Against the trend, OrbiMed opened a new position in Elevance Health worth $66.7M.

  • OrbiMed's largest Q4 2023 buy was Elevance Health: 141,500 shares worth $66.7M.
  • OrbiMed added most to Eli Lilly in Q4 2023, an estimated $105M increase.
  • OrbiMed's biggest Q4 2023 reduction was Humana, cutting an estimated $115M.
  • OrbiMed fully exited Mirati Therapeutics, Inc. Common Stock in Q4 2023, selling an estimated $85.3M.
  • OrbiMed's ten largest holdings make up 36% of its $5.01B portfolio in Q4 2023.
  • OrbiMed opened 15 new positions and closed 32 in Q4 2023.
  • OrbiMed's portfolio value rose 6.4% quarter-over-quarter to $5.01B.

Based on OrbiMed's 13F filing for Q4 2023, filed 14 Feb 2024.